CITY OF INDUSTRY, Calif., Dec. 23 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc would like to update its shareholders on their November 29th, request to Roche in response to the need for greater TAMIFLU(R) production.
Due to the increased demand for TAMIFLU(R) and increased concerns over potential influenza pandemic, Roche (the makers of TAMIFLU(R)) has decided to look for parties interested in toll manufacturing of dosage forms or oseltamivir API (active pharmaceutical ingredient) for Roche’s antiviral drug TAMIFLU(R). The interested parties will help fulfill the demands from the United States and other countries world-wide.
The company recently received a letter from Dr. Bernhard Scholl and Dr. Isabelle Conrot Bouley at Roche, thanking them for its efforts to support with the manufacturing of the medicine. Roche expressed interest in contacting the company for future projects but was unable to extend an award to proceed with the TAMIFLU production.
A specialist team in Roche has carefully evaluated the information received from a larger number of individuals and companies. Each offer was surveyed and compared to the other ones, and against the overall capacities needed. The aim was to define how the immediate need to speed up and further enhance the supply of TAMIFLU(R) can be best achieved.
Roche has identified 12 potential partners to produce TAMIFLU(R) out of about 200 applicants. The 12 partner firms include pharmaceutical firms, generic manufacturers, and specialty chemicals producers.
Safe Harbor Statement
Included in this release are certain “forward-looking” statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense’s financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense’s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact: U.S. BioDefense, Inc. David Chin 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc
CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
